Efficacy and Safety of Budesonide Foam for Patients With Active Mild to Moderate Ulcerative Proctitis or Proctosigmoiditis



Status:Recruiting
Conditions:Colitis, Gastrointestinal
Therapuetic Areas:Gastroenterology
Healthy:No
Age Range:18 - Any
Updated:3/30/2013
Start Date:November 2009
Contact:Chantelle McGee
Email:chantelle.mcgee@salix.com
Phone:919-447-3176

Use our guide to learn which trials are right for you!

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Budesonide Foam Versus Placebo in Subjects With Active Mild to Moderate Ulcerative Proctitis or Proctosigmoiditis


The purpose of this study is to establish the efficacy profile of rectally administered
budesonide foam administered as 2mg/25mL BID for 2 weeks followed by 2mg/25mL QD for 4
weeks, as compared to an equivalent volume of rectally administered placebo foam over the
same dosing schedule, in subjects who present with a diagnosis of active, mild to moderate,
ulcerative proctitis (UP) or ulcerative proctosigmoiditis (UPS). During the study, eligible
subjects will be allowed to maintain previously established oral 5-ASA treatment at doses up
to 4.8g/day.


This is a Phase 3, randomized, double-blind, placebo-controlled, multi-center study to
assess the efficacy and safety of budesonide foam in subjects with active mild to moderate
proctitis or proctosigmoiditis. Approximately 430 subjects will be enrolled into the study
and receive either placebo foam or budesonide foam twice a day for 2 weeks followed by once
a day for 4 weeks. Participation in the study will last approximately 11 weeks, depending
on the timing of study visits.

During the study, eligible subjects will be allowed to maintain previously established oral
5-ASA treatment at doses up to 4.8g/day. Periodic safety monitoring, including physical
examinations, vitals, laboratory testing, and recording of AEs and concomitant medications,
will be performed during the study

Inclusion Criteria:

- Voluntarily sign written informed consent.

- Male or non-pregnant and non-lactating females ≥18 years of age.

- Confirmed diagnosis (by endoscopy procedure) of active, mild to moderate ulcerative
proctitis or proctosigmoiditis extending no further than 40cm from the anal verge.

- Must possess a baseline MMDAI score between 5 and 10.

- Visible blood in stool.

Exclusion Criteria:

- History or current diagnosis of Crohn's disease and indeterminate colitis.

- Prior gastrointestinal surgery except appendectomy and hernia.

- Concomitant active gastrointestinal disease or distortion of intestinal anatomy.

- History of diverticulitis, collagenous colitis, celiac disease, recurrent pancreatic
or known gallbladder disease.

- Uncontrolled, previously diagnosed type 1 or 2 diabetes mellitus.

- Uncontrolled abnormal thyroid function.

- Unstable significant cardiovascular, endocrine, neurologic or pulmonary disease.

- Hemoglobin levels < 7.5 g/dL.

- History of sclerosing cholangitis, cirrhosis, or hepatic impairment.

- Renal disease manifested by > 2.0mg/dL serum creatinine.

- History of avascular hip necrosis, active tuberculosis, ocular herpes simplex or
ocular varicella zoster, malignant disease, and HIV or hepatitis B or C.

- Adrenal insufficiency.

- Active systemic or cutaneous infection or toxic megacolon, fistula, perforation or
abscess.

- History of uncontrolled psychiatric disorders or seizure disorders.

- History of asthma requiring ongoing use of inhaled steroids.

- Recent history of drug or alcohol abuse.

- Positive stool test for bacterial pathogens, C diff or O&P.

- Vaccination within 28 days prior to Randomization.

- Allergies to budesonide or to any other items used in its preparation.

- Participation in another clinical trial in the past 30 days.

- Pregnant or at risk of pregnancy.

- Taking a prohibited medication. Some medications to treat UP/UPS are prohibited
during participation in the study, including laxatives and anti-diarrhea medications;
however, oral 5-ASA agents at doses up to 4.8g/day and daily fiber supplements are
allowed. Other medications (e.g., antibiotics, anti-seizure and anti-coagulant
medicines) are also prohibited.
We found this trial at
28
sites
?
mi
from
Dallas, TX
Click here to add this to my saved trials
?
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
?
mi
from
Ashville, NC
Click here to add this to my saved trials
?
mi
from
Aurora, CO
Click here to add this to my saved trials
?
mi
from
Baltimore, MD
Click here to add this to my saved trials
?
mi
from
Bettendorf, IA
Click here to add this to my saved trials
?
mi
from
Birmingham, AL
Click here to add this to my saved trials
?
mi
from
Bridgeport, CT
Click here to add this to my saved trials
?
mi
from
Chattanooga, TN
Click here to add this to my saved trials
?
mi
from
Cleveland, OH
Click here to add this to my saved trials
?
mi
from
Daytona Beach, FL
Click here to add this to my saved trials
?
mi
from
Decatur, GA
Click here to add this to my saved trials
?
mi
from
Fort Smith, AR
Click here to add this to my saved trials
?
mi
from
Jackson, MS
Click here to add this to my saved trials
?
mi
from
Metairie, LA
Click here to add this to my saved trials
?
mi
from
Milwaukee, WI
Click here to add this to my saved trials
?
mi
from
New York, NY
Click here to add this to my saved trials
?
mi
from
Newark, NJ
Click here to add this to my saved trials
?
mi
from
Norfolk, VA
Click here to add this to my saved trials
?
mi
from
Overland Park, KS
Click here to add this to my saved trials
?
mi
from
Park Ridge, IL
Click here to add this to my saved trials
?
mi
from
Phoenix, AZ
Click here to add this to my saved trials
?
mi
from
Portland, OR
Click here to add this to my saved trials
?
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
?
mi
from
Santa Clara, CA
Click here to add this to my saved trials
?
mi
from
Seattle, WA
Click here to add this to my saved trials
?
mi
from
St. Joseph, MO
Click here to add this to my saved trials
?
mi
from
Tulsa, OK
Click here to add this to my saved trials